.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Predict branded drug patent expiration
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Moodys
Novartis
Express Scripts
Citi
Cantor Fitzgerald
US Army
McKinsey
QuintilesIMS
Accenture
McKesson

Generated: July 21, 2017

DrugPatentWatch Database Preview

Claims for Patent: 4,436,741

« Back to Dashboard

Claims for Patent: 4,436,741

Title: Method for administering scopolamine transdermally
Abstract:Method and therapeutic system in the form of a bandage that administer scopolamine base transdermally in an initial pulse of 10 to 200 .mu.g/cm.sup.2 of skin that quickly brings the concentration of scopolamine in the plasma to a level at which emesis and nausea are inhibited without intolerable side effects, followed by a substantially constant dosage in the range of 0.3 to 15 .mu.g/hr that holds said level. The bandage is a four-layer laminate of, from the top: a protective backing; a gelled, mineral oil-polyisobutene-scopolamine reservoir lamina that is the source of the constant dosage; a microporous membrane that controls the constant dosage rate; and a gelled, mineral oil-polyisobutene-scopolamine adhesive layer that is the source of the pulse dose and the means by which the bandage is attached to the skin.
Inventor(s): Urquhart; John (Palo Alto, CA), Chandrasekaran; Santosh K. (Palo Alto, CA), Shaw; Jane E. (Atherton, CA)
Assignee: ALZA Corporation (Palo Alto, CA)
Application Number:06/474,754
Patent Claims: 1. A method for administering scopolamine transdermally for a prolonged time period comprising administering scopolamine base to a predetermined area of unbroken skin in a skin saturating initial dose of about 10 to about 200 .mu.g/cm.sup.2 of skin and thereafter at a substantially constant rate in the range of about 0.3 to about 15 .mu.g/hr which rate is sufficient to maintain the urinary excretion of scopolamine in the range of from 0.05 to about 1.5 .mu.g/hr for said prolonged period of time.

2. A method for administering scopolamine transdermally for a prolonged period of time comprising:

(a) administering scopolamine base to a predetermined area of unbroken skin until sufficient scopolamine has been administered to occupy the scopolamine binding sites associated with said area of skin and;

(b) after said binding site have been occupied continuously administering scopolamine to said area of skin at a substantially constant rate in the range of about 0.3 to about 15 .mu.g/hr for said prolonged period of time.

3. The method of claim 2 wherein said area of skin is located at the mastoidal area.

4. The method of claim 2 wherein the scopolamine is administered to the skin of a subject suffering from a vestibular disturbance.

5. The method of claim 2 wherein the substantially constant rate is about 5 to 15 .mu.g/hr for adults and 3 to 10 .mu.g/hr for children.

6. The method of claim 3 wherein the substantially constant rate is about 5 to 15 .mu.g/hr for adults and 3-10 .mu.g/hr for children.

7. The method of claim 5 wherein said scopolamine binding sites are saturated by the administration of a dose of about 10 to about 200 .mu.g/cm.sup.2 of skin.

8. The method of claim 2 wherein the scopolamine is administered to the skin of a pregnant subject.

9. The method of claim 2 wherein the scopolamine is administered to the skin of a subject undergoing chemotherapy.

10. The method of claim 2 wherein the scopolamine is administered to the skin of a subject undergoing radiation therapy.

11. The method of claim 2 wherein the scopolamine is administered to the skin of a subject treated with an anesthetic.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Harvard Business School
Baxter
UBS
Johnson and Johnson
McKinsey
Farmers Insurance
Chubb
US Army
Express Scripts
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot